Is the biotech boom start­ing to fade? The roar­ing ‘20s starts to look a lit­tle fa­tigued. Plus: Top 5 deals, IPOs, pacts of Q3

Biotech deal cash con­tin­ued to gush through Q3, but a care­ful look at the de­tails in ag­gre­gate sug­gests that the rosy tint to the biotech boom has start­ed to lose some of its col­or.

Once again, deal mas­ter Chris Doko­ma­ji­lar at Deal­For­ma has crunched the num­bers on all the gauges we use to as­sess the per­for­mance of the biotech sec­tor. And there’s been a dis­tinct cool­ing of over­all ac­tiv­i­ty, par­tic­u­lar­ly around IPOs and ven­ture cash in­fu­sions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN